Tumor-Treating Fields: A Fourth Modality in Cancer Treatment
Abstract
Abstract Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. Clin Cancer Res; 24(2); 266–75. ©2017 AACR.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Data from clinical trials and extensive safety studies in healthy animals have shown that TTFields are not associated with significant systemic toxicities.
“Although we have not tested the effect of TTFields on cytoskeletal architecture of non-cancerous cells, data from clinical trials and extensive safety studies in healthy animals have shown that TTFields are not associated with significant systemic toxicities [7,37].”
From Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics (2020) · cites this paper as [7]
The citation lists haven’t been fetched yet
References 75 · Cited by 380
- Authors
- Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D.
- Affiliations
- University of Washington (US)
- Translational Genomics Research Institute (US)
- 3Novocure Ltd., Topaz Building, MATAM Center, Haifa, Israel.
- 4Virginia G. Piper Cancer Center Clinical Trials, HonorHealth Research Institute, Scottsdale, Arizona.
- Corresponding author
- Mun, Elijah J.
- Venue
- Clinical Cancer Research
- Published
- 2018-01-15
- Volume
- 24
- Issue
- 2
- Pages
- 266-275
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2740953687
- Cited by
- 380
- References
- 75
- Citations by year
- 2026: 28 · 2025: 46 · 2024: 66 · 2023: 62 · 2022: 79 · 2021: 40 · 2020: 29 · 2019: 17 · 2018: 13
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Stand Up To Cancer (SU2C-AACR-DT0509)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Electromagnetic Fields and Biological Effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
- Keywords
- tumor treating fields, AC electric field, mitotic arrest, apoptosis, glioblastoma, antitumor immunity, noninvasive cancer therapy, treatment toxicity
- MeSH terms
- Animals, Clinical Trials as Topic, Combined Modality Therapy, Humans, Neoplasms, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
